高级检索
    朱军. 2周或3周CHOP加或不加依托泊苷治疗无不良预后因素(LDH正常)年轻侵袭性淋巴瘤NHL-B1临床试验结果[J]. 循证医学, 2007, 7(1): 15-17. DOI: 10.3969/j.issn.1671-5144.2007.01.006
    引用本文: 朱军. 2周或3周CHOP加或不加依托泊苷治疗无不良预后因素(LDH正常)年轻侵袭性淋巴瘤NHL-B1临床试验结果[J]. 循证医学, 2007, 7(1): 15-17. DOI: 10.3969/j.issn.1671-5144.2007.01.006
    shu
    ZHU Jun. Two-Weekly or Three-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Young Patients with Good-Prognosis (Normal LDH) Aggressive Lymphomas: Results of the NHL-B1 Trial of the DSHNHL[J]. Journal of Evidence-Based Medicine, 2007, 7(1): 15-17. DOI: 10.3969/j.issn.1671-5144.2007.01.006
    Citation: ZHU Jun. Two-Weekly or Three-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Young Patients with Good-Prognosis (Normal LDH) Aggressive Lymphomas: Results of the NHL-B1 Trial of the DSHNHL[J]. Journal of Evidence-Based Medicine, 2007, 7(1): 15-17. DOI: 10.3969/j.issn.1671-5144.2007.01.006
    shu

    2周或3周CHOP加或不加依托泊苷治疗无不良预后因素(LDH正常)年轻侵袭性淋巴瘤NHL-B1临床试验结果

    Two-Weekly or Three-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Young Patients with Good-Prognosis (Normal LDH) Aggressive Lymphomas: Results of the NHL-B1 Trial of the DSHNHL

      摘要
      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回